We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adeza (NASDAQ:ADZA) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation covering...
Adeza (NASDAQ:ADZA) today announced financial results for the quarter ended September 30, 2006 and updated 2006 financial guidance. Adeza reported record product sales of...
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson, president and chief executive officer, will make an investment community presentation at the Rodman & Renshaw 8th...
Adeza (Nasdaq:ADZA) today announced preliminary record product sales for the three months ended September 30, 2006 of approximately $13.5 million, an increase of $2.0 million or...
Adeza (NASDAQ:ADZA) today announced that the U.S. Food and Drug Administration (FDA) has determined that Gestiva? for the prevention of preterm birth in women with a history of...
Adeza (NASDAQ:ADZA) today announced that Emory V. Anderson, president and chief executive officer, will make an investment community presentation at the UBS Global Life Sciences Conference on...
Adeza (NASDAQ: ADZA) today announced that Emory V. Anderson, president and chief executive officer, will make investment community presentations at two conferences: ? -- The Thomas Weisel...
Adeza (NASDAQ:ADZA) today announced that the Reproductive Health Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) recommended by a majority vote that the data presented by...
Adeza (NASDAQ:ADZA) today announced that Nancy D. Burrus, general partner of Indosuez Ventures, resigned from the company's board of directors. Ms. Burrus was also a member of the board's...
Adeza (NASDAQ:ADZA) today announced financial results for the second quarter ended June 30, 2006. ? Adeza reported record product sales of $13.0 million for the second quarter of 2006, an increase...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions